www.hivandhepatitis.com

Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

EASL 2008: Sorafenib (Nexavar) Improves Outcomes in Patients with Hepatocellular Carcinoma

Details
Category: Liver Cancer/HCC
Published on Friday, 16 May 2008 00:00
Written by Liz Highleyman
  • Print

In a late-breaker presentations at the 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008) last month in Milan, researchers discussed data from the SHARP study, which evaluated sorafenib (Nexavar) as a therapy for HCC. Sorafenib, which was already approved for primary kidney cancer, recently received U.S. Food and Drug Administration (FDA) approval for unresectable (not curable by surgery) HCC.

alt

Read more:

Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design